TOKYO--(BUSINESS WIRE)--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company, today announced the successful dosing of the first patient in its domestic Phase I/II EMERALD study of HS-005, ...
Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...
The intention-to-treat population comprised 544 patients: 273 in the intervention group and 271 in the control group. The mean (±SD) age was 58.2±13.5 years, and 42.6% of the patients were women. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results